{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:41:57Z","timestamp":1791250917689,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"am","delay-in-days":237,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S10OD028488"],"award-info":[{"award-number":["S10OD028488"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01GM098285"],"award-info":[{"award-number":["R01GM098285"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006710","name":"Wayne State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"NIH National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35 GM149213"],"award-info":[{"award-number":["R35 GM149213"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejmech.2025.117792","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T15:20:02Z","timestamp":1747840802000},"page":"117792","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Investigation into the binding domains of platelet factor 4 unlocks new avenues for the design and synthesis of selective sulfated pseudo-tetrasaccharide aminoglycoside ligands"],"prefix":"10.1016","volume":"295","author":[{"given":"Livia","family":"Philip","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hawau","family":"Abdulsalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kartikey","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7626-8439","authenticated-orcid":false,"given":"Hien M.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117792_bib1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1055\/s-0038-1645072","article-title":"Human platelet factor 4 and its C-terminal peptides: heparin binding and clearance from the circulation","volume":"63","author":"Rucinski","year":"1990","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ejmech.2025.117792_bib2","first-page":"151","article-title":"Biochemistry of alpha granule proteins","volume":"22","author":"Holt","year":"1985","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.ejmech.2025.117792_bib3","doi-asserted-by":"crossref","first-page":"12376","DOI":"10.1074\/jbc.274.18.12376","article-title":"Characterization of a neutrophil cell surface glycosaminoglycan that mediates binding of platelet factor 4","volume":"274","author":"Petersen","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.117792_bib4","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/0003-9861(85)90049-9","article-title":"The interaction of platelet factor four and glycosaminoglycans","volume":"240","author":"Loscalzo","year":"1985","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ejmech.2025.117792_bib5","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-2004-831048","article-title":"Interactions of platelet factor 4 with the vessel wall","volume":"30","author":"Sachais","year":"2004","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.ejmech.2025.117792_bib6","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1146\/annurev.biochem.68.1.729","article-title":"Functions of cell surface heparan sulfate proteoglycans","volume":"68","author":"Bernfield","year":"1999","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejmech.2025.117792_bib7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/978-3-642-23056-1_8","article-title":"Heparin and heparan sulfate: analyzing structure and microheterogeneity","author":"Shriver","year":"2012","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117792_bib8","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1146\/annurev-biochem-060713-035314","article-title":"Demystifying heparan sulfate\u2013protein interactions","volume":"83","author":"Xu","year":"2014","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejmech.2025.117792_bib9","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1039\/b100916h","article-title":"Heparin and heparan sulfate: structure and function","volume":"19","author":"Rabenstein","year":"2002","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.ejmech.2025.117792_bib10","doi-asserted-by":"crossref","first-page":"8361","DOI":"10.1021\/bi00193a025","article-title":"Crystal structure of recombinant human platelet factor 4","volume":"33","author":"Zhang","year":"1994","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2025.117792_bib11","doi-asserted-by":"crossref","first-page":"8277","DOI":"10.1038\/ncomms9277","article-title":"Atomic description of the immune complex involved in heparin-induced thrombocytopenia","volume":"6","author":"Cai","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117792_bib12","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S0140-6736(86)90233-3","article-title":"Localisation of heparin in mast cells","volume":"328","author":"Scully","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.117792_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168960","article-title":"Effects of primary mast cell disease on hemostasis and erythropoiesis","volume":"22","author":"Seidel","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.117792_bib14","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/pgmj.2007.059188","article-title":"Heparin induced thrombocytopenia: diagnosis and management update","volume":"83","author":"Ahmed","year":"2007","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.ejmech.2025.117792_bib15","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1182\/blood-2016-11-709873","article-title":"Heparin-induced thrombocytopenia","volume":"129","author":"Arepally","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117792_bib16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1161\/ATVBAHA.120.315445","article-title":"Heparin-induced thrombocytopenia: a focus on thrombosis","volume":"41","author":"Arepally","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejmech.2025.117792_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/antib9040052","article-title":"Structural features and PF4 functions that occur in heparin-induced thrombocytopenia (HIT) complicated by COVID-19","volume":"9","author":"Cai","year":"2020","journal-title":"Antibodies"},{"key":"10.1016\/j.ejmech.2025.117792_bib18","first-page":"192","article-title":"Heparin: effects upon the glycocalyx and endothelial cells, J. Extra. Corpor","volume":"49","author":"Spiess","year":"2017","journal-title":"Tech"},{"key":"10.1016\/j.ejmech.2025.117792_bib19","doi-asserted-by":"crossref","first-page":"5285","DOI":"10.1182\/blood-2011-06-359430","article-title":"PF4\/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of Fc\u03b3RI","volume":"119","author":"Kasthuri","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117792_bib20","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1182\/blood-2013-11-539262","article-title":"Platelet transactivation by monocytes promotes thrombosis in heparin-induced thrombocytopenia","volume":"127","author":"Tutwiler","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117792_bib21","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00063198-200007000-00016","article-title":"Venous thromboembolism in heparin-induced thrombocytopenia","volume":"6","author":"Warkentin","year":"2000","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.ejmech.2025.117792_bib22","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.1021\/acsami.0c20744","article-title":"Inhibition of tumor\u2013host cell interactions using synthetic heparin mimetics","volume":"13","author":"Gockel","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ejmech.2025.117792_bib23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bcp.2014.02.010","article-title":"The potential of heparanase as a therapeutic target in cancer","volume":"89","author":"Pisano","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117792_bib24","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.drup.2016.10.001","article-title":"Heparanase: from basic research to therapeutic applications in cancer and inflammation, drug","volume":"29","author":"Vlodavsky","year":"2016","journal-title":"Resist. Updat."},{"key":"10.1016\/j.ejmech.2025.117792_bib25","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1093\/jnci\/djh230","article-title":"Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis","volume":"96","author":"Edovitsky","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ejmech.2025.117792_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/cells7120236","article-title":"Heparanase: a multitasking protein involved in extracellular matrix (ECM) remodeling and intracellular events","volume":"7","author":"Masola","year":"2018","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2025.117792_bib27","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.exphem.2016.08.006","article-title":"Mechanisms of heparanase inhibitors in cancer therapy","volume":"44","author":"Heyman","year":"2016","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.ejmech.2025.117792_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.01316","article-title":"Heparanase: a challenging cancer drug target","volume":"9","author":"Coombe","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2025.117792_bib29","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.3324\/haematol.2017.182865","article-title":"Phase I study of the heparanase inhibitor roneparstat: an innovative approach for ultiple myeloma therapy","volume":"103","author":"Galli","year":"2018","journal-title":"Haematologica (Roma)"},{"key":"10.1016\/j.ejmech.2025.117792_bib30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/107602960100700210","article-title":"Anticoagulant and antiprotease profiles of a novel natural heparinomimetic mannopentaose phosphate sulfate (PI-88)","volume":"7","author":"Demir","year":"2001","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"10.1016\/j.ejmech.2025.117792_bib31","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/s41416-018-0006-0","article-title":"A phase I study of the novel immunomodulatory agent PG545 (Pixatimod) in subjects with advanced solid tumours","volume":"118","author":"Dredge","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.117792_bib32","doi-asserted-by":"crossref","first-page":"20457","DOI":"10.1074\/jbc.M414546200","article-title":"Identification and characterization of heparin\/heparan sulfate binding domains of the endoglycosidase heparanase","volume":"280","author":"Levy-Adam","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.117792_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021106","article-title":"M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis","volume":"6","author":"Zhou","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.117792_bib34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10637-007-9080-5","article-title":"A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma","volume":"26","author":"Lewis","year":"2008","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ejmech.2025.117792_bib35","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/1078-0432.CCR-10-2476","article-title":"SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase\/syndecan-1 axis","volume":"17","author":"Ritchie","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117792_bib36","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006136","article-title":"Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors","volume":"11","author":"Lemech","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ejmech.2025.117792_bib37","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1182\/blood-2014-09-599498","article-title":"Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study","volume":"125","author":"Kang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117792_bib38","first-page":"13","article-title":"Fondaparinux-associated heparin-induced thrombocytopenia","volume":"25","author":"Burch","year":"2012","journal-title":"SAVE Proc."},{"key":"10.1016\/j.ejmech.2025.117792_bib39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1527-3466.2002.tb00081.x","article-title":"Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors","volume":"20","author":"Bauer","year":"2002","journal-title":"Cardiovasc. Drug Rev."},{"key":"10.1016\/j.ejmech.2025.117792_bib40","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.1021\/acs.jmedchem.0c00156","article-title":"Modulating heparanase activity: tuning sulfation pattern and glycosidic linkage of oligosaccharides","volume":"63","author":"Zhu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117792_bib41","article-title":"Synthesis of a systematic 64-Membered heparan sulfate tetrasaccharide library","volume":"62","author":"Baryal","year":"2023","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2025.117792_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpa.2024.102455","article-title":"Recent advances in the synthesis of extensive libraries of heparan sulfate oligosaccharides for structure-activity relationship studies","volume":"80","author":"Ramadan","year":"2024","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.117792_bib43","first-page":"441","article-title":"Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity, inter","volume":"41","author":"Avent","year":"2011","journal-title":"Med. J."},{"key":"10.1016\/j.ejmech.2025.117792_bib44","article-title":"Aminoglycosides: an overview, csh perspect","volume":"6","author":"Krause","year":"2016","journal-title":"Med"},{"key":"10.1016\/j.ejmech.2025.117792_bib45","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/nsmb.3136","article-title":"Structural characterization of human heparanase reveals insights into substrate recognition","volume":"22","author":"Wu","year":"2015","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.117792_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.966754","article-title":"Evaluating the immunogenicity of heparin and heparin derivatives by measuring their binding to platelet factor 4 using biolayer interferometry","volume":"9","author":"Chen","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ejmech.2025.117792_bib47","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202304325","article-title":"Rational design and expedient synthesis of heparan sulfate mimetics from natural aminoglycosides for structure and activity relationship studies","volume":"62","author":"Wakpal","year":"2023","journal-title":"Angew. Chem. Int. Ed"},{"key":"10.1016\/j.ejmech.2025.117792_bib48","article-title":"Structural insights into pixatimod (PG545) inhibition of heparanase, a key enzyme in cancer and viral infections","volume":"28","author":"Chhabra","year":"2022","journal-title":"Chemistry"},{"key":"10.1016\/j.ejmech.2025.117792_bib49","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13058-024-01906-6","article-title":"The role of heparan sulfate in enhancing the chemotherapeutic response in triple-negative breast cancer","volume":"26","author":"Manouchehri","year":"2024","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117792_bib50","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/leu.2014.121","article-title":"Heparanase enhances myeloma progression via CXCL10 downregulation","volume":"28","author":"Barash","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.117792_bib51","first-page":"8749","article-title":"High heparanase activity in multiple myeloma is associated with elevated microvessel density","volume":"63","author":"Kelly","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117792_bib52","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3892\/or.2020.7641","article-title":"Heparanase potentiates the invasion and migration of pancreatic cancer cells via epithelial-to-mesenchymal transition through the Wnt\/\u03b2-catenin pathway","volume":"44","author":"Wang","year":"2020","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejmech.2025.117792_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039474","article-title":"Syndecan-1 enhances proliferation, migration and metastasis of HT-1080 cells in cooperation with syndecan-2","volume":"7","author":"P\u00e9terfia","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.117792_bib54","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3892\/mmr.2017.6638","article-title":"Elemene inhibits the migration and invasion of 4T1 murine breast cancer cells via heparanase","volume":"16","author":"Zhang","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejmech.2025.117792_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052175","article-title":"PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model","volume":"7","author":"Hammond","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.117792_bib56","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41389-018-0060-8","article-title":"Identification of strong intron enhancer in the heparanase gene: effect of functional rs4693608 variant on HPSE enhancer activity in hematological and solid malignancies","volume":"7","author":"Ostrovsky","year":"2018","journal-title":"Oncogenesis"},{"key":"10.1016\/j.ejmech.2025.117792_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/cells9092038","article-title":"Nuclear heparanase regulates chromatin remodeling, gene expression and PTEN tumor suppressor function","volume":"9","author":"Amin","year":"2020","journal-title":"Cells"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425005574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425005574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T20:28:00Z","timestamp":1749241680000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425005574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":57,"alternative-id":["S0223523425005574"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117792","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigation into the binding domains of platelet factor 4 unlocks new avenues for the design and synthesis of selective sulfated pseudo-tetrasaccharide aminoglycoside ligands","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117792","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117792"}}